Potential impact of introducing the pneumococcal conjugate vaccine into national immunization programmes: an economic-epidemiological analysis using data from India

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pneumococcal pneumonia causes an estimated 105,000 child deaths in India annually. The planned introduction of the serotype-based pneumococcal conjugate vaccine (PCV) is expected to avert child deaths, but the high cost of PCV relative to current vaccines provided under the Universal Immunization Programme has been a concern. Cost-effectiveness studies from high-income countries are not readily comparable because of differences in the distribution of prevalent serotypes, population, and health systems. We used IndiaSim, an agent-based simulation model representative of the Indian population and health system, to model the dynamics of Streptococcus pneumoniae. We estimate that PCV13 introduction would cost approximately $240 million and avert $48.7 million in out-of-pocket expenditures and 34,800 (95% confidence interval [CI] 29,600–40,800) deaths annually assuming coverage levels and distribution similar to DPT (diphtheria, pertussis, and tetanus) vaccination (~77%). Introducing the vaccine protects the population, especially the poorest wealth quintile, from potentially catastrophic expenditure. The net-present value of predicted money-metric value of insurance for 20 years of vaccination is $160,000 (95% CI $151,000–$168,000) per 100,000 under-fives, and almost half of this protection is for the bottom wealth quintile ($78,000; 95% CI 70,800—84,400). Extending vaccination to 90% coverage averts additional lives and provides additional financial risk protection. Our estimates are sensitive to immunity parameters in our model; however, our assumptions are conservative, and if willingness to pay per years of life lost (YLL) averted is $228 or greater then introducing the vaccine is more cost-effective than our baseline (no vaccination) in more than 95% of simulations.
LanguageEnglish
Article numbere000636
Number of pages12
JournalBMJ Global Health
Volume3
Issue number3
Early online date9 May 2018
DOIs
Publication statusE-pub ahead of print - 9 May 2018

Fingerprint

Immunization Programs
Conjugate Vaccines
Pneumococcal Vaccines
India
Vaccination
Economics
Vaccines
Confidence Intervals
Health Expenditures
Costs and Cost Analysis
Pneumococcal Pneumonia
Population
Diphtheria
Whooping Cough
Health
Tetanus
Streptococcus pneumoniae
Insurance
Cost-Benefit Analysis
Immunity

Keywords

  • pneumococcal disease
  • pneumonia
  • pneumococcal conjugate vaccine
  • treptococcus pneumoniae
  • pharmacoeconomics

Cite this

@article{77b0fb00c514423c9bbefd822a5b3d76,
title = "Potential impact of introducing the pneumococcal conjugate vaccine into national immunization programmes: an economic-epidemiological analysis using data from India",
abstract = "Pneumococcal pneumonia causes an estimated 105,000 child deaths in India annually. The planned introduction of the serotype-based pneumococcal conjugate vaccine (PCV) is expected to avert child deaths, but the high cost of PCV relative to current vaccines provided under the Universal Immunization Programme has been a concern. Cost-effectiveness studies from high-income countries are not readily comparable because of differences in the distribution of prevalent serotypes, population, and health systems. We used IndiaSim, an agent-based simulation model representative of the Indian population and health system, to model the dynamics of Streptococcus pneumoniae. We estimate that PCV13 introduction would cost approximately $240 million and avert $48.7 million in out-of-pocket expenditures and 34,800 (95{\%} confidence interval [CI] 29,600–40,800) deaths annually assuming coverage levels and distribution similar to DPT (diphtheria, pertussis, and tetanus) vaccination (~77{\%}). Introducing the vaccine protects the population, especially the poorest wealth quintile, from potentially catastrophic expenditure. The net-present value of predicted money-metric value of insurance for 20 years of vaccination is $160,000 (95{\%} CI $151,000–$168,000) per 100,000 under-fives, and almost half of this protection is for the bottom wealth quintile ($78,000; 95{\%} CI 70,800—84,400). Extending vaccination to 90{\%} coverage averts additional lives and provides additional financial risk protection. Our estimates are sensitive to immunity parameters in our model; however, our assumptions are conservative, and if willingness to pay per years of life lost (YLL) averted is $228 or greater then introducing the vaccine is more cost-effective than our baseline (no vaccination) in more than 95{\%} of simulations.",
keywords = "pneumococcal disease, pneumonia, pneumococcal conjugate vaccine , treptococcus pneumoniae, pharmacoeconomics",
author = "Itamar Megiddo and Eili Klein and Ramanan Laxminarayan",
year = "2018",
month = "5",
day = "9",
doi = "10.1136/bmjgh-2017-000636",
language = "English",
volume = "3",
journal = "BMJ Global Health",
issn = "2059-7908",
number = "3",

}

TY - JOUR

T1 - Potential impact of introducing the pneumococcal conjugate vaccine into national immunization programmes

T2 - BMJ Global Health

AU - Megiddo, Itamar

AU - Klein, Eili

AU - Laxminarayan, Ramanan

PY - 2018/5/9

Y1 - 2018/5/9

N2 - Pneumococcal pneumonia causes an estimated 105,000 child deaths in India annually. The planned introduction of the serotype-based pneumococcal conjugate vaccine (PCV) is expected to avert child deaths, but the high cost of PCV relative to current vaccines provided under the Universal Immunization Programme has been a concern. Cost-effectiveness studies from high-income countries are not readily comparable because of differences in the distribution of prevalent serotypes, population, and health systems. We used IndiaSim, an agent-based simulation model representative of the Indian population and health system, to model the dynamics of Streptococcus pneumoniae. We estimate that PCV13 introduction would cost approximately $240 million and avert $48.7 million in out-of-pocket expenditures and 34,800 (95% confidence interval [CI] 29,600–40,800) deaths annually assuming coverage levels and distribution similar to DPT (diphtheria, pertussis, and tetanus) vaccination (~77%). Introducing the vaccine protects the population, especially the poorest wealth quintile, from potentially catastrophic expenditure. The net-present value of predicted money-metric value of insurance for 20 years of vaccination is $160,000 (95% CI $151,000–$168,000) per 100,000 under-fives, and almost half of this protection is for the bottom wealth quintile ($78,000; 95% CI 70,800—84,400). Extending vaccination to 90% coverage averts additional lives and provides additional financial risk protection. Our estimates are sensitive to immunity parameters in our model; however, our assumptions are conservative, and if willingness to pay per years of life lost (YLL) averted is $228 or greater then introducing the vaccine is more cost-effective than our baseline (no vaccination) in more than 95% of simulations.

AB - Pneumococcal pneumonia causes an estimated 105,000 child deaths in India annually. The planned introduction of the serotype-based pneumococcal conjugate vaccine (PCV) is expected to avert child deaths, but the high cost of PCV relative to current vaccines provided under the Universal Immunization Programme has been a concern. Cost-effectiveness studies from high-income countries are not readily comparable because of differences in the distribution of prevalent serotypes, population, and health systems. We used IndiaSim, an agent-based simulation model representative of the Indian population and health system, to model the dynamics of Streptococcus pneumoniae. We estimate that PCV13 introduction would cost approximately $240 million and avert $48.7 million in out-of-pocket expenditures and 34,800 (95% confidence interval [CI] 29,600–40,800) deaths annually assuming coverage levels and distribution similar to DPT (diphtheria, pertussis, and tetanus) vaccination (~77%). Introducing the vaccine protects the population, especially the poorest wealth quintile, from potentially catastrophic expenditure. The net-present value of predicted money-metric value of insurance for 20 years of vaccination is $160,000 (95% CI $151,000–$168,000) per 100,000 under-fives, and almost half of this protection is for the bottom wealth quintile ($78,000; 95% CI 70,800—84,400). Extending vaccination to 90% coverage averts additional lives and provides additional financial risk protection. Our estimates are sensitive to immunity parameters in our model; however, our assumptions are conservative, and if willingness to pay per years of life lost (YLL) averted is $228 or greater then introducing the vaccine is more cost-effective than our baseline (no vaccination) in more than 95% of simulations.

KW - pneumococcal disease

KW - pneumonia

KW - pneumococcal conjugate vaccine

KW - treptococcus pneumoniae

KW - pharmacoeconomics

UR - http://gh.bmj.com/

U2 - 10.1136/bmjgh-2017-000636

DO - 10.1136/bmjgh-2017-000636

M3 - Article

VL - 3

JO - BMJ Global Health

JF - BMJ Global Health

SN - 2059-7908

IS - 3

M1 - e000636

ER -